Breaking Down Revenue Trends: argenx SE vs Arrowhead Pharmaceuticals, Inc.

Biotech Revenue Race: argenx SE vs Arrowhead Pharmaceuticals

__timestamp	Arrowhead Pharmaceuticals, Inc.	argenx SE
Wednesday, January 1, 2014	175000	4579319.93
Thursday, January 1, 2015	382000	7504448.39
Friday, January 1, 2016	158333	15466459
Sunday, January 1, 2017	31407709	43793829
Monday, January 1, 2018	16142321	24564806
Tuesday, January 1, 2019	168795577	78116087
Wednesday, January 1, 2020	87992066	44848173
Friday, January 1, 2021	138287000	497277000
Saturday, January 1, 2022	243231000	410746000
Sunday, January 1, 2023	240735000	1226316000
Monday, January 1, 2024	3551000

Infusing magic into the data realm

Revenue Trends: A Tale of Two Biotechs

In the competitive world of biotechnology, revenue growth is a key indicator of a company's success. Over the past decade, argenx SE and Arrowhead Pharmaceuticals, Inc. have shown distinct revenue trajectories. Starting in 2014, Arrowhead's revenue was modest, but by 2022, it had surged by over 1,300%, peaking at approximately $243 million. Meanwhile, argenx SE, which began with a revenue of around $4.6 million in 2014, experienced a staggering growth of over 26,000% by 2023, reaching approximately $1.23 billion. This remarkable growth highlights argenx SE's strategic advancements in the biotech sector. However, 2024 data for argenx SE is missing, leaving room for speculation on its future trajectory. These trends underscore the dynamic nature of the biotech industry, where innovation and strategic investments can lead to exponential growth.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025